Jump to content

Breast biopsy

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 12:44, 16 December 2020 (Task 18 (cosmetic): eval 17 templates: del empty params (5×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

See also: Biopsy
Surgical Breast Biopsy
Surgeon doing a surgical breast biopsy
ICD-9-CM85.11-85.12

A breast biopsy is usually done after a suspicious lesion is discovered on either Mammography or Ultrasound in order to get tissue for pathological diagnosis.[1] Several methods for a breast biopsy now exist.[2] The most appropriate method of biopsy for a patient depends upon a variety of factors, including the size, location, appearance and characteristics of the abnormality.[3] The different types of breast biopsies include fine needle aspiration (FNA), vacuum assisted biopsy, core needle biopsy, and surgical excision biopsy.[3][4][5] Breast biopsies can be done under ultrasound, MRI or a Stereotactic biopsy technique.[2][5][4][6] Vacuum assisted biopsies are typically done using stereotactic techniques when the suspicious lesion can only be seen on mammography.[5] On average, 5-10 biopsies of a suspicious breast lesion will lead to the diagnosis of one case of breast cancer.[7]

Indications

There are many reasons why your doctor may order a breast biopsy.[7] Typical indications include:

  • A suspicious area on mammography or ultrasound.[8] This may include:
    • Microcalcifications on MRI.[9]
    • BI-RADS score of 4 or 5 on mammography, ultrasound, or MRI.[10]
  • A suspicious hard palpable lump[8]
  • Skin changes like crusting, scaling, or dimpling of the breast, which may signal an underlying breast cancer[8]
  • Abnormal nipple discharge [7][8]

Fine needle aspiration

Main article: Fine-needle aspiration
Fine Needle Aspiration

Fine needle aspiration (FNA) is a percutaneous ("through the skin") procedure that uses a fine needle and a syringe to sample fluid from a breast cyst or remove clusters of cells from a solid mass.[6] It is mainly used to differentiate between a cyst and a mass.[6] If the aspirated contents are not cyst-like, then a tissue sample must be taken to better evaluate the mass.[6] Fine needle aspiration is one of the most commonly used initial diagnostic tools for suspicious lesions.[11] The doctor will typically use a 22 or 27 gauge needle to aspirate out free fluid and cells.[11] It can be done in an outpatient setting and is associated with minimal pain.[11] However, in up to 30% of cases, pathological slides from fine needle aspiration of breast lesions may be inconclusive, necessitating the need for further testing.[11] FNA can be done to aspirate the contents of a cyst, which may relieve any pain that the cyst caused, or can be used to aspirate a suspicious lesion in conjunction with cytology (cellular analysis).[12] If aspirating the contents of a cyst, the aspirate is usually not sent for cytology unless it is bloody.[12] If the cyst is not detectable by touch, it may be located using ultrasound, MRI, or stereotactic mammography.[12] Recovery time from an outpatient FNA is minimal.[12]

Core needle biopsy

Core needle biopsy (CNB) is another percutaneous ("through the skin") method of breast biopsy that became more popular than FNA in the 1990s due to the larger sample of tissue CNB provides.[13] This method is usually done under ultrasound guidance and involves using two needles, one inner "puncture" needle that is inserted into the mass, and a wider gauge needle with an open "gap" or "trough" on one side that allows for tissue to enter.[10] A spring-loaded sheath then is triggered by the technician that covers the trough in the needle to allow sample tissue to be separated and removed for analysis.[10] Typically 4 tissue samples are removed to minimize sample error. To prevent the need to pierce the breast repeatedly a coaxial needle left in place on top of the mass as a guide.[10] CNB has a higher sensitivity for cancer than FNA, has lower false negatives, and has proven more successful in finding rare breast diseases like lobular carcinoma. However, this method still has relatively high rates of false negatives compared to surgical or vacuum assisted methods due to the overall low volume of tissue removed.[13][10] Also, because breast tissue can be difficult to target on ultrasound, as much as 5-10% of suspicious lesions are missed by the needle and may result in a high rate of false negatives, or the need for additional biopsies.[13]

Vacuum assisted breast biopsy

Vacuum assisted breast biopsy (VABB) is a more recent version of core needle biopsy using a vacuum technique to assist the collection of the tissue sample. Similarly to core needle biopsy the needle has a lateral ("from the side") opening and can be rotated allowing multiple samples to be collected through a single skin incision. This method has become more popular than FNA, CNB, and surgical biopsies due to the benefits of low invasiveness while still obtaining a larger tissue sample.[13] Taking more tissue helps reduce sampling error since breast lesions are often heterogeneous (cancer cells are spread unevenly) and therefore cancer can be missed if not enough tissue is taken. VABB can be guided by stereotactic (most popular), ultrasound, and MRI, and can yield as much as 2g of tissue sample.[13] The vacuum assisted biopsy category also includes automated rotational core devices.[14]

Direct and frontal biopsy

Recent innovations in tissue acquisition for the human breast have led to the development of unique direct frontal systems. Efficacy is considered optimal if the diagnosis by transcutaneous biopsy is identical to the surgical specimen in case of malignancy or in line with clinical follow-up when benign.[citation needed]

The direct and frontal biopsy systems can even be considered relatively painless. The quality of the sample is sufficient for research on molecular biology.[15][16][17]

Excisional (surgical) biopsy

Surgical breast biopsy specimen that has been inked on all sides to aid a Pathologist in evaluating tissue margins under the microscope.

Excisional biopsy involves surgically removing the suspicious area of the breast to examine it under the microscope for diagnosis. One method is wire guided (or wire-localized) excisional biopsy, where a wire is inserted into the breast and repeatedly imaged until the technician sees that the tip is located in the area to be removed, which is then taken out surgically.[9] When the tissue is removed, it is processed by a Pathologist, who describes the tissue as it appears by eye, and inks the sides to help orient the tissue under the microscope after it is sliced.[9] Each color corresponds to a direction, such as superior, inferior, medial, lateral, anterior, and posterior (these correspond to top, bottom, outside, inside, front, and back).[9] When the tissue is then looked at under the microscope, the margins can then be evaluated to see if they are free of cancer cells, or if the surgeon needs to go back and remove more tissue from that area.[9] Titanium surgical clips are often left behind by surgeons to help future physicians locate the site and monitor for future disease or target the area with radiation if needed.[9] Percutaneous ("through the skin") biopsy methods have become more favored over surgical biopsies due to the high rate of benign findings (80%) and the reduction of adverse effects such as scarring.[10]

Adverse Effects

Radiographic Marker in a Lumpectomy Specimen

Adverse effects of breast biopsies tend to vary depending on what type of biopsy is performed. The more invasive, such as surgery, tend to have more severe types of adverse incidents, whereas less invasive such as FNA or CNB tend to have less severe. For vacuum assisted biopsies, some complications of the procedure can include bleeding, post operative pain, and hematoma formation.[13] However, most can be avoided with proper application of pressure and rest.[13] Some examples of adverse effects of core needle biopsies can include rare biopsy risks like infection, abscess formation, fistula formation, migration of any markers placed in the breast, and potential seeding of the tumor (causing displacement of cancer cells due to the procedure that can start new tumors elsewhere).[1][18] Another potential adverse effect occurs when taking a biopsy of an area of microcalcification. If the entire area of microcalcification is removed, it is then very difficult to find the suspicious area in the future for treatment. A marker is placed in the suspicious area to help localize the proper area for possible removal at a later date, if this is removed during biopsy, it can be difficult to make sure that the correct area was excised in surgery.[18] Bleeding into the site of the suspicious lesion caused by the biopsy procedure can appear to look like a complex cyst on ultrasound, which could lead to additional unnecessary management.[12] The false negative rate of the results of a breast biopsy is approximately 1%.[12]

Global breast biopsy devices market is forecasted to generate a revenue of $1.4 billion by 2023,- P&S Market Research.

References

  1. ^ a b Jain A, Khalid M, Qureshi MM, Georgian-Smith D, Kaplan JA, Buch K, Grinstaff MW, Hirsch AE, Hines NL, Anderson SW, Gallagher KM, Bates DD, Bloch BN (November 2017). "Stereotactic core needle breast biopsy marker migration: An analysis of factors contributing to immediate marker migration". European Radiology. 27 (11): 4797–4803. doi:10.1007/s00330-017-4851-7. PMID 28526892.
  2. ^ a b Wang M, He X, Chang Y, Sun G, Thabane L (February 2017). "A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysis". Breast. 31: 157–166. doi:10.1016/j.breast.2016.11.009. PMID 27866091.
  3. ^ a b Zare Mehrjardi, Mohammad; Keshavarz, Elham; Ebrahimi, Afshar; Izadpanah, Ensieh (2016-05-03). "Complications associated with ultrasound-guided breast core needle biopsy (CNB)". Zenodo. doi:10.5281/zenodo.1038518.
  4. ^ a b Fernández-García P, Marco-Doménech SF, Lizán-Tudela L, Ibáñez-Gual MV, Navarro-Ballester A, Casanovas-Feliu E (January 2017). "The cost effectiveness of vacuum-assisted versus core-needle versus surgical biopsy of breast lesions". Radiologia. 59 (1): 40–46. doi:10.1016/j.rx.2016.09.006. PMID 27865561.
  5. ^ a b c Esen G, Tutar B, Uras C, Calay Z, İnce Ü, Tutar O (July 2016). "Vacuum-assisted stereotactic breast biopsy in the diagnosis and management of suspicious microcalcifications". Diagnostic and Interventional Radiology. 22 (4): 326–33. doi:10.5152/dir.2015.14522. PMC 4956017. PMID 27306660.
  6. ^ a b c d Dinas K, Pratilas GC, Nasioutziki M, Vavoulidis E, Makris V, Loufopoulos PD, Kalder M (September 2018). "Clinical Significance of Fine Needle Aspiration in Managing Patients with Breast Lesions". Folia Medica. 60 (3): 364–372. doi:10.2478/folmed-2018-0002. PMID 30355841.
  7. ^ a b c Jameson, J. Harrison's Principles of Internal Medicine. Breast Cancer: McGraw-Hill.
  8. ^ a b c d Gantenbein H, Spieler P (November 1986). "[Fine-needle aspiration biopsy of the breast. Frequency, indication and accuracy, studied on material from the Cytological Laboratory of the Pathology Institute, St. Gallen Canton Hospital, 1981-1984]". Schweizerische Medizinische Wochenschrift. 116 (44): 1513–8. PMID 3024311.
  9. ^ a b c d e f Niederhuber, John E.; Armitage, James O.; Doroshow, James H.; Kastan, Michael B.; Tepper, Joel E. (2013-09-12). Abeloff's clinical oncology. Niederhuber, John E.,, Armitage, James O., 1946-, Doroshow, James H.,, Kastan, M. B. (Michael B.),, Tepper, Joel E.,, Abeloff, Martin D. (Fifth ed.). Philadelphia, Pennsylvania. ISBN 9781455728817. OCLC 857585932.{{cite book}}: CS1 maint: location missing publisher (link)
  10. ^ a b c d e f MD, Fischer, Uwe (2017-12-13). Breast cancer : diagnostic imaging and therapeutic guidance. Baum, Friedemann,, Luftner-Nagel, Susanne. Stuttgart. ISBN 9783132019416. OCLC 961213945.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: multiple names: authors list (link)
  11. ^ a b c d Joudeh AA, Shareef SQ, Al-Abbadi MA (2016). "Fine-Needle Aspiration Followed by Core-Needle Biopsy in the Same Setting: Modifying Our Approach". Acta Cytologica. 60 (1): 1–13. doi:10.1159/000444386. PMID 26963594.
  12. ^ a b c d e f YM, Michael (2011). Basic Radiology. Chapter 5: McGraw-Hill.{{cite book}}: CS1 maint: location (link)
  13. ^ a b c d e f g Park, Hai-Lin; Hong, Jisun (May 2014). "Vacuum-assisted breast biopsy for breast cancer". Gland Surgery. 3 (2): 120–127. doi:10.3978/j.issn.2227-684X.2014.02.03. ISSN 2227-684X. PMC 4115763. PMID 25083505.
  14. ^ "ADVANCE for Health Information Professionals - Editorial". advanceweb.com.
  15. ^ Cornelis A, Verjans M, Van den Bosch T, Wouters K, Van Robaeys J, Janssens JP (August 2009). "Efficacy and safety of direct and frontal macrobiopsies in breast cancer". European Journal of Cancer Prevention. 18 (4): 280–4. doi:10.1097/CEJ.0b013e328329d885. PMID 19352188. S2CID 15348590.
  16. ^ High-Precision Direct and Frontal Breast Biopsy to Assure Adequate Surgical Margin Interpretation; Jaak Janssens, MD, PhD; Ruediger Schulz-Wendtland, MD, PhD; Luc Rotenberg, MD; John-Paul Bogers, MD, PhD
  17. ^ Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. (June 2011). "Exemestane for breast-cancer prevention in postmenopausal women". The New England Journal of Medicine. 364 (25): 2381–91. doi:10.1056/NEJMoa1103507. hdl:2445/135519. PMID 21639806.
  18. ^ a b Nathan C, Rolland Y (2002). "Pharmacological treatments that affect CNS activity: serotonin". Annals of the New York Academy of Sciences. 499 (Suppl 1): 277–96. doi:10.1186/bcr513. PMC 3300487.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Breast_biopsy&oldid=994575358"